Market Price

59.00 

-0.57 -1.0%

as of Jul 19 '19

52 Week Range:

53.00 68.69


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; insitro Inc.; Nurix Therapeutics, Inc.; and Carna Biosciences Inc., as well as the Chengdu Hi-tech Zone. The company was founded in 1987 and is headquartered in Foster City, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 1.62
2.19
2.69
3.14
4.28
5.16
7.45
11.21
12.18
15.91
15.60
growth rate 35.2% 22.8% 16.7% 36.3% 20.6% 44.4% 50.5% 8.7% 30.6% -2.0%
Earnings BIT 2,152.33
2,759.40
3,082.64
2,877.66
2,846.12
3,319.16
15,265.00
22,193.00
18,065.00
14,124.00
9,020.00
growth rate 28.2% 11.7% -6.7% -1.1% 16.6% 359.9% 45.4% -18.6% -21.8% -36.1%
Avg.PE 24.57
15.22
11.04
10.54
22.22
40.98
12.53
6.92
6.68
18.42
14.20
growth rate -38.1% -27.5% -4.5% 110.8% 84.4% -69.4% -44.8% -3.5% 175.8% -22.9%
ROA 31.29
31.53
27.25
19.41
13.45
14.06
42.34
41.87
24.81
7.27
8.14
growth rate 0.8% -13.6% -28.8% -30.7% 4.5% 201.1% -1.1% -40.8% -70.7% 12.0%
ROE 52.84
50.11
47.44
44.49
32.30
29.74
90.32
106.64
72.16
23.53
26.08
growth rate -5.2% -5.3% -6.2% -27.4% -7.9% 203.7% 18.1% -32.3% -67.4% 10.8%
ROIC 38.43
40.46
34.41
24.45
17.87
18.53
54.17
54.50
33.57
9.83
12.09
growth rate 5.3% -15.0% -29.0% -26.9% 3.7% 192.3% 0.6% -38.4% -70.7% 23.0%
Cur. Ratio 3.52
2.57
2.32
5.53
1.44
1.14
3.07
2.50
2.22
2.74
3.38
growth rate -27.0% -9.7% 138.4% -74.0% -20.8% 169.3% -18.6% -11.2% 23.4% 23.4%
Quick Ratio 2.30
1.63
1.51
4.71
0.85
0.66
2.56
2.07
1.78
2.52
3.15
growth rate -29.1% -7.4% 211.9% -82.0% -22.4% 287.9% -19.1% -14.0% 41.6% 25.0%
Leverage 1.69
1.52
1.98
2.57
2.28
1.98
2.25
2.80
3.02
3.44
2.98
growth rate -10.1% 30.3% 29.8% -11.3% -13.2% 13.6% 24.4% 7.9% 13.9% -13.4%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 744.32
1,095.48
1,278.78
1,538.33
1,380.80
1,655.88
4,635.00
5,854.00
4,514.00
3,851.00
3,327.00
growth rate 47.2% 16.7% 20.3% -10.2% 19.9% 179.9% 26.3% -22.9% -14.7% -13.6%
Acct.Payable 955.00
1,178.00
1,206.00
814.00
790.00
growth rate 23.4% 2.4% -32.5% -3.0%
Cur.Assets 3,111.68
3,794.25
4,500.27
10,973.58
4,853.63
5,734.66
17,714.00
24,762.00
19,588.00
31,823.00
35,836.00
growth rate 21.9% 18.6% 143.8% -55.8% 18.2% 208.9% 39.8% -20.9% 62.5% 12.6%
Total Assets 5,045.13
7,646.38
9,139.61
13,641.76
16,745.46
17,736.48
34,664.00
51,716.00
56,977.00
70,283.00
63,675.00
growth rate 51.6% 19.5% 49.3% 22.8% 5.9% 95.4% 49.2% 10.2% 23.4% -9.4%
Cash 1,061.35
1,003.63
715.79
7,792.39
1,422.04
1,665.73
10,027.00
12,851.00
8,229.00
7,588.00
17,940.00
growth rate -5.4% -28.7% 988.6% -81.8% 17.1% 502.0% 28.2% -36.0% -7.8% 136.4%
Inventory 674.86
829.24
949.08
1,095.88
1,375.76
1,620.79
1,386.00
1,955.00
1,587.00
801.00
814.00
growth rate 22.9% 14.5% 15.5% 25.5% 17.8% -14.5% 41.1% -18.8% -49.5% 1.6%
Cur.Liabilities 888.03
1,475.57
1,943.41
1,982.67
3,341.16
4,986.95
5,761.00
9,890.00
9,218.00
11,635.00
10,605.00
growth rate 66.2% 31.7% 2.0% 68.5% 49.3% 15.5% 71.7% -6.8% 26.2% -8.9%
Liabilities 1,937.75
2,626.55
4,516.66
8,328.89
9,411.29
8,773.08
18,830.00
32,601.00
37,614.00
49,782.00
42,141.00
growth rate 35.6% 72.0% 84.4% 13.0% -6.8% 114.6% 73.1% 15.4% 32.4% -15.4%
LT Debt 839.74
979.82
2,237.95
5,996.33
5,561.85
3,105.27
11,921.00
21,073.00
26,346.00
30,795.00
24,574.00
growth rate 16.7% 128.4% 167.9% -7.3% -44.2% 283.9% 76.8% 25.0% 16.9% -20.2%
Equity 3,107.46
5,019.82
4,622.94
5,312.95
7,334.17
8,963.40
15,441.00
18,536.00
18,887.00
20,442.00
21,387.00
growth rate 61.5% -7.9% 14.9% 38.0% 22.2% 72.3% 20.0% 1.9% 8.2% 4.6%
Common Shares 1,918.00
1,868.00
1,747.00
1,580.00
1,583.00
1,695.00
1,647.00
1,521.00
1,358.00
1,319.00
1,308.00
growth rate -2.6% -6.5% -9.6% 0.2% 7.1% -2.8% -7.7% -10.7% -2.9% -0.8%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 115.01
230.06
61.88
131.90
397.05
557.00
747.00
748.00
590.00
924.00
growth rate 100.0% -73.1% 113.2% 201.0% 18.4% 34.1% 0.1% -21.1% 56.6%
Cash Dividends 0.00
0.00
-95.34
83.38
0.00
0.00
1,874.00
1,874.00
2,455.00
2,731.00
2,971.00
growth rate 100.0% -100.0% 0.0% 31.0% 11.2% 8.8%
Cash From OA 1,558.89
2,428.35
2,234.25
2,868.99
2,518.70
2,447.98
12,818.00
21,250.00
17,047.00
11,898.00
8,400.00
growth rate 55.8% -8.0% 28.4% -12.2% -2.8% 423.6% 65.8% -19.8% -30.2% -29.4%
FCF per Share 0.73
0.94
1.26
1.56
1.61
1.17
4.95
10.44
11.75
7.46
5.27
growth rate 28.8% 34.0% 23.8% 3.2% -27.3% 323.1% 110.9% 12.6% -36.5% -29.4%
Sale Purchase of Stock 331.00
319.00
208.00
-720.00
growth rate -3.6% -34.8% -100.0%
FCF 2,090.00
2,850.00
2,772.00
3,507.00
2,798.00
2,914.00
12,261.00
19,582.00
15,921.00
11,308.00
7,476.00
growth rate 36.4% -2.7% 26.5% -20.2% 4.2% 320.8% 59.7% -18.7% -29.0% -33.9%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 3,880.73
5,527.79
6,267.31
6,611.05
7,649.45
8,831.42
24,890.00
32,639.00
30,390.00
26,107.00
22,127.00
growth rate 42.4% 13.4% 5.5% 15.7% 15.5% 181.8% 31.1% -6.9% -14.1% -15.2%
Op.Income 1,948.07
2,782.42
3,123.80
2,987.88
3,161.64
3,566.72
15,265.00
22,193.00
18,065.00
14,124.00
9,020.00
growth rate 42.8% 12.3% -4.4% 5.8% 12.8% 328.0% 45.4% -18.6% -21.8% -36.1%
IBT 1,943.85
2,760.98
3,085.40
2,878.45
2,847.70
3,317.74
14,856.00
21,659.00
17,097.00
13,529.00
7,799.00
growth rate 42.0% 11.8% -6.7% -1.1% 16.5% 347.8% 45.8% -21.1% -20.9% -42.4%
Net Income 1,439.25
2,078.06
2,287.38
2,210.36
2,043.22
2,424.17
12,101.00
18,108.00
13,501.00
4,628.00
5,455.00
growth rate 44.4% 10.1% -3.4% -7.6% 18.6% 399.2% 49.6% -25.4% -65.7% 17.9%
EPS 1.03
1.41
1.66
1.77
1.64
1.81
7.35
11.91
9.94
3.51
4.17
growth rate 36.9% 17.7% 6.6% -7.3% 10.4% 306.1% 62.0% -16.5% -64.7% 18.8%
Gross Profit 3,060.84
4,269.82
4,793.08
4,936.17
5,701.08
6,577.78
21,102.00
28,633.00
26,129.00
21,736.00
17,274.00
growth rate 39.5% 12.3% 3.0% 15.5% 15.4% 220.8% 35.7% -8.8% -16.8% -20.5%
R&D 524.97
741.02
845.87
969.10
1,387.51
1,671.25
2,854.00
3,014.00
4,666.00
3,734.00
4,198.00
growth rate 41.2% 14.2% 14.6% 43.2% 20.5% 70.8% 5.6% 54.8% -20.0% 12.4%

Quarterly Statements

Item Name Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Earnings BIT 2,153.00
2,280.00
2,623.00
1,964.00
2,237.00
growth rate 5.9% 15.0% -25.1% 13.9%
Balance Sheet Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Acct.Receivable 3,775.00
3,541.00
3,465.00
3,327.00
3,283.00
growth rate -6.2% -2.2% -4.0% -1.3%
Acct.Payable 711.00
623.00
580.00
790.00
577.00
growth rate -12.4% -6.9% 36.2% -27.0%
Cur.Assets 30,258.00
32,728.00
34,918.00
35,836.00
34,024.00
growth rate 8.2% 6.7% 2.6% -5.1%
Total Assets 65,381.00
65,355.00
64,305.00
63,675.00
62,837.00
growth rate 0.0% -1.6% -1.0% -1.3%
Cash 7,643.00
13,234.00
14,569.00
17,940.00
16,927.00
growth rate 73.2% 10.1% 23.1% -5.7%
Inventory 885.00
859.00
816.00
814.00
898.00
growth rate -2.9% -5.0% -0.3% 10.3%
Cur.Liabilities 10,670.00
10,912.00
10,116.00
10,605.00
9,397.00
growth rate 2.3% -7.3% 4.8% -11.4%
Liabilities 44,730.00
43,621.00
41,298.00
42,141.00
40,746.00
growth rate -2.5% -5.3% 2.0% -3.3%
LT Debt 26,557.00
26,062.00
24,570.00
24,574.00
24,509.00
growth rate -1.9% -5.7% 0.0% -0.3%
Equity 20,591.00
21,672.00
22,861.00
21,387.00
21,951.00
growth rate 5.3% 5.5% -6.5% 2.6%
Common Shares 1.00
1.00
1.00
1.00
1.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Capital Expenditures 212.00
297.00
167.00
248.00
237.00
growth rate 40.1% -43.8% 48.5% -4.4%
Cash Dividends 753.00
740.00
742.00
736.00
817.00
growth rate -1.7% 0.3% -0.8% 11.0%
Cash From OA 2,270.00
1,573.00
2,212.00
2,345.00
1,444.00
growth rate -30.7% 40.6% 6.0% -38.4%
Sale Purchase of Stock 111.00
48.00
growth rate -56.8%
FCF 2,058.00
1,276.00
2,045.00
2,097.00
1,207.00
growth rate -38.0% 60.3% 2.5% -42.4%
Income Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Sales 5,088.00
5,648.00
5,596.00
5,795.00
5,281.00
growth rate 11.0% -0.9% 3.6% -8.9%
Op.Income 2,153.00
2,280.00
2,623.00
1,964.00
2,237.00
growth rate 5.9% 15.0% -25.1% 13.9%
IBT 2,033.00
2,086.00
2,664.00
1,016.00
2,350.00
growth rate 2.6% 27.7% -61.9% 131.3%
Net Income 1,538.00
1,817.00
2,097.00
3.00
1,975.00
growth rate 18.1% 15.4% -99.9% 65,733.3%
EPS
growth rate
Gross Profit 4,087.00
4,452.00
4,510.00
4,225.00
4,324.00
growth rate 8.9% 1.3% -6.3% 2.3%
R&D 937.00
1,192.00
939.00
1,130.00
1,057.00
growth rate 27.2% -21.2% 20.3% -6.5%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (42.28)

YOY Growth Grade:

D (36.95)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 13.01 13.02 10.99
EPS / Growth 4.53

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 14.5%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 14.5% 14.5% 14.5%
Future PE 10.99 17.65 17.65
Future EPS 17.52 17.52 17.52
Value Price
MOS %
47.60
-19.3%
76.46
29.6%
76.46
29.6%
MOS Price 23.80 38.23 38.23
IRT 7.19 7.19 7.19

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.